Immune response to COVID-19 vaccination in immunocompromised hosts (IRVAX) study
The Royal Melbourne Hospital in collaboration with the Doherty Institute are examining the immune response to individuals with inflammatory bowel disease to COVID-19 vaccination. This is in order to determine whether individuals who are taking immunosuppressive medications get the same level of protection from the vaccine, and whether this is sustained, compared to individuals who are not taking medication.
This involves a series of 5 blood tests, the first of which occurs at Royal Melbourne Hospital at any point in time prior to your first vaccine dose. Blood tests will occur at different time points after vaccination.
To be eligible the study, you must be:
- Aged 16 years and over
- Have a confirmed diagnosis of inflammatory bowel disease
- Have not yet received your first COVID-19 vaccination yet, but plan to
- Take medications to manage your IBD
To learn more about the study, please contact Dr Eva Zhang at [email protected].